These results also implicate that the prostate cancer cells in CRPC can shift to employ alternative pathways of DHT biosynthesis via their flexible or adaptive transcriptional control of androgen synthestic enzyme genes by different nuclear receptors including ERRα and LRH-1. This evidence concerns the gene ESRRA and prostate cancer.